PRME
Prime Medicine, Inc. NASDAQ Listed Oct 20, 2022$3.18
+1.92%
vs $3.12
Mkt Cap $574.4M
52w Low $2.28
19.3% of range
52w High $6.94
50d MA $3.29
200d MA $3.95
P/E (TTM)
—
EV/EBITDA
—
P/B
3.9x
Debt/Equity
1.0x
ROE
-166.4%
P/FCF
-2.8x
RSI (14)
42.20
ATR (14)
$0.27
Beta
2.67
50d MA
$3.29
200d MA
$3.95
Avg Volume
2.9M
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
21 Erie Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 3.41 | +0.0% | -8.5% | +2.9% | +0.9% | +1.9% | -0.9% | — |
| Mar 3, 2026 | AMC | -0.25 | -0.22 | +12.0% | 4.23 | +1.2% | -2.6% | -4.6% | +2.0% | +2.5% | -1.5% | — |
| Nov 7, 2025 | AMC | -0.28 | -0.32 | -14.3% | 3.81 | +7.3% | -7.3% | +11.0% | -9.4% | -6.2% | +1.2% | — |
| Aug 7, 2025 | AMC | -0.36 | -0.41 | -13.9% | 3.68 | -0.3% | +3.0% | -7.4% | -1.4% | +10.1% | -4.5% | — |
| May 8, 2025 | AMC | -0.32 | -0.40 | -25.0% | 1.32 | +0.8% | -1.5% | +3.1% | -5.2% | -4.7% | +4.1% | — |
| Feb 28, 2025 | AMC | -0.37 | -0.31 | +16.2% | 2.52 | +2.8% | -11.1% | -1.3% | +4.5% | -0.4% | +4.3% | — |
| Nov 12, 2024 | AMC | -0.43 | -0.44 | -2.3% | 4.32 | -6.7% | -8.3% | -9.1% | -6.9% | -5.1% | -0.3% | — |
| Aug 8, 2024 | AMC | -0.40 | -0.46 | -15.0% | 4.39 | -1.4% | -4.3% | -1.7% | +3.9% | -4.2% | +6.8% | — |
| May 10, 2024 | AMC | -0.45 | -0.44 | +2.2% | 5.61 | +4.8% | +14.4% | +3.7% | +1.5% | +4.1% | +0.6% | — |
| Mar 1, 2024 | AMC | -0.48 | -0.56 | -16.7% | 8.74 | +1.9% | +0.3% | -8.0% | +4.3% | -3.3% | -0.7% | — |
| Nov 3, 2023 | AMC | -0.45 | -0.55 | -22.2% | 7.80 | +2.1% | -0.5% | +7.1% | -9.7% | -8.7% | -0.6% | — |
| Aug 7, 2023 | AMC | -0.42 | -0.47 | -11.9% | 12.55 | -2.5% | +1.3% | +0.1% | -4.6% | -3.6% | +4.6% | — |
| May 11, 2023 | AMC | -0.42 | -0.44 | -4.8% | 12.55 | -0.7% | +1.4% | +1.4% | -2.6% | +3.7% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | Citigroup | Maintains | Neutral → Neutral | — | $3.53 | $3.50 | -0.8% | +11.0% | -9.4% | -6.2% | +1.2% | +13.4% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $3.81 | $4.09 | +7.3% | -7.3% | +11.0% | -9.4% | -6.2% | +1.2% |
| Aug 12 | Citigroup | Maintains | Neutral → Neutral | — | $3.51 | $3.60 | +2.6% | -1.4% | +10.1% | -4.5% | -1.9% | -2.0% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $3.68 | $3.67 | -0.3% | +3.0% | -7.4% | -1.4% | +10.1% | -4.5% |
| May 27 | Citigroup | Downgrade | Buy → Neutral | — | $1.29 | $1.26 | -2.3% | -1.6% | +0.0% | -0.8% | -6.3% | +0.8% |
| May 20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.34 | $1.33 | -0.7% | -11.9% | -0.8% | +5.1% | +4.9% | -1.6% |
| May 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.34 | $1.33 | -0.7% | -11.9% | -0.8% | +5.1% | +4.9% | -1.6% |
| May 20 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.34 | $1.33 | -0.7% | -11.9% | -0.8% | +5.1% | +4.9% | -1.6% |
| May 19 | Chardan Capital | Maintains | Buy → Buy | — | $1.59 | $1.39 | -12.6% | -15.7% | -11.9% | -0.8% | +5.1% | +4.9% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $2.00 | $2.06 | +3.0% | +0.5% | -3.0% | +4.1% | -3.9% | +0.0% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.77 | +0.6% | +13.6% | +0.5% | -3.0% | +4.1% | -3.9% |
| Mar 4 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $2.24 | $2.19 | -2.2% | -1.3% | +4.5% | -0.4% | +4.3% | -13.3% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.52 | $2.59 | +2.8% | -11.1% | -1.3% | +4.5% | -0.4% | +4.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.59 | +2.8% | -11.1% | -1.3% | +4.5% | -0.4% | +4.3% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | $3.45 | $3.46 | +0.3% | -9.3% | +1.9% | -6.9% | +10.1% | -1.5% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.18 | -0.5% | -4.0% | +4.5% | -3.1% | -0.2% | -4.7% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.39 | $4.33 | -1.4% | -4.3% | -1.7% | +3.9% | -4.2% | +6.8% |
| May 16 | Citigroup | Upgrade | Neutral → Buy | — | $6.76 | $6.90 | +2.1% | +4.1% | +0.6% | +6.4% | +6.6% | -7.2% |
| May 13 | JP Morgan | Maintains | Overweight → Overweight | — | $5.61 | $5.88 | +4.8% | +14.4% | +3.7% | +1.5% | +4.1% | +0.6% |
| Apr 23 | Wedbush | Maintains | Outperform → Outperform | — | $4.78 | $4.85 | +1.5% | +0.4% | -2.1% | -8.5% | +3.0% | +9.7% |
| Mar 8 | JP Morgan | Maintains | Overweight → Overweight | — | $8.14 | $8.40 | +3.2% | -0.7% | -0.6% | -4.0% | +2.9% | -13.1% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $8.77 | $8.65 | -1.4% | -8.0% | +4.3% | -3.3% | -0.7% | -0.6% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $7.76 | $7.77 | +0.1% | +7.1% | -9.7% | -8.7% | -0.6% | -2.1% |
| Aug 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.69 | $11.66 | -0.3% | +4.6% | -2.3% | -2.7% | +1.8% | +0.8% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $16.74 | $16.63 | -0.7% | +0.7% | +0.5% | +1.7% | +1.3% | -2.8% |
No insider trades available.
8-K
Prime Medicine, Inc. -- 8-K Filing
Prime Medicine stockholders approved the re-election of directors and ratified PwC as the independent auditor for fiscal 2026.
Jun 8
8-K · 2.02
!! High
Prime Medicine, Inc. -- 8-K 2.02: Earnings Results
Prime Medicine reported financial results through an 8-K filing, with detailed earnings information available in the attached press release exhibit for investor review.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
PRME's new CFO hire signals operational maturity and potential financial restructuring; investors should monitor whether improved financial controls and capital allocation justify the added executive compensation costs.
Apr 16
8-K · 7.01
! Medium
Prime Medicine, Inc. -- 8-K 7.01: Regulation FD Disclosure
Prime Medicine updated its corporate presentation on March 3, 2026, providing investors with current company information through their investor relations website.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alphabet Inc. | 16,562,498 | $57M | — | Dec 2025 |
| 2 | Ark Investment Management Llc | 6,246,827 | $22M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 4,474,162 | $16M | New | Mar 2026 |
| 4 | Woodline Partners Lp | 3,003,313 | $10M | — | Mar 2026 |
| 5 | Ubs Group Ag | 2,888,418 | $10M | Added | Mar 2026 |
| 6 | Morgan Stanley | 2,339,796 | $8M | Added | Dec 2025 |
| 7 | Adar1 Capital Management, Llc | 1,973,282 | $7M | New | Mar 2026 |
| 8 | Fmr Llc | 1,769,476 | $6M | Reduced | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 1,572,811 | $5M | Reduced | Mar 2026 |
| 10 | D.e. Shaw & Co | 1,393,621 | $5M | Reduced | Mar 2026 |
| 11 | Farallon Capital Management Llc | 1,240,843 | $4M | New | Mar 2026 |
| 12 | Northern Trust Corp | 886,716 | $3M | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 862,204 | $3M | New | Mar 2026 |
| 14 | Jpmorgan Chase & Co | 844,154 | $3M | Added | Mar 2026 |
| 15 | Greenwich Wealth Management Llc | 750,001 | $3M | Added | Mar 2026 |
| 16 | Renaissance Technologies Llc | 741,039 | $3M | Reduced | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 715,829 | $2M | Reduced | Mar 2026 |
| 18 | Hrt Financial Lp | 612,769 | $2M | Reduced | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 577,004 | $2M | Added | Mar 2026 |
| 20 | Aqr Capital Management Llc | 554,935 | $2M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$574.4M
Enterprise Value
$394.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.14x
P/B
3.91x
P/S
117.27x
P/FCF
-2.78x
EV/EBITDA
—
Shares Out
148.8M
Financials (TTM)
Revenue
$4.0M
Net Income
-$198.4M
EBITDA
-$190.9M
Free Cash Flow
-$167.1M
Op Cash Flow
-$162.6M
EPS Basic
$-1.35
EPS Diluted
$-1.27
EPS Forward
$-0.94
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$342.7M
Total Liab.
$221.9M
Total Equity
$120.9M
Cash
$177.7M
LT Debt
$108.3M
Book Value/Sh
$0.81
Debt/Equity
0.96x
Current Ratio
4.84
Quick Ratio
4.84
Returns & Growth
ROE
-166.4%
ROA
-58.7%
ROIC
-66.5%
Rev Growth YoY
+55.3%
EPS Growth YoY
+18.3%
Price Returns
2W
+13.4%
1M
+0.0%
3M
-23.2%
6M
-7.1%
12M
+200.8%
Technicals
52W High
$6.94
52W Low
$2.28
50d MA
$3.29
200d MA
$3.95
RSI (14)
42.20
ATR (14)
$0.27
Beta
2.67
Avg Volume
2.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Sep 10, 2019
Analyst Price Targets
Consensus
$17.25
High
$23.00
Low
$12.00
Median
$17.00
Data updated apr 26, 2026 8:46pm
· Source: financialmodelingprep.com